PRNewsWire · 30 Sept 2026positive
CytoSorbents announced that it will present new data on its CytoSorb blood purification technology at the European Association for Cardio-Thoracic Surgery Annual Meeting in Barcelona (October 7-10, 2026) and at the European Society of Intensive Care Medicine Annual Congress in Lisbon (October 10-14, 2026), covering open heart surgery and critical care applications.
Why it matters — The upcoming presentations highlight CytoSorb's clinical evidence across cardiac surgery and critical care at major international conferences, which could raise the product's visibility among key medical professionals.
PRNewsWire · 23 Sept 2026positive
CytoSorbents Corporation announced that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share. The company, which uses blood purification to treat life-threatening conditions in the ICU and cardiac surgery, made the announcement on September 23, 2026.
Why it matters — Regaining compliance removes the risk of delisting from Nasdaq, which is material to CTSO shareholders and the company's continued listing status.
PRNewsWire · 10 Sept 2026neutral
CytoSorbents Corporation announced it will participate in the upcoming H.C. Wainwright 28th Annual Global Investment Conference, as disclosed in a Sept. 10, 2026 press release from Princeton, N.J. The company, which specializes in blood purification for life-threatening conditions in the intensive care unit and cardiac surgery, noted its attendance at the event.
Why it matters — A CTSO watcher would care because the company's participation at a major investment conference provides an opportunity for leadership to present to investors and potentially raise its visibility in the financial community.
Newsfile Corp · 4 Sept 2026neutral
CytoSorbents announced that CEO Dr. Phillip Chan and CFO Peter Mariani will attend the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9-10, 2026, in New York City, where they will deliver an investor presentation and hold scheduled one-on-one meetings with investors.
Why it matters — CTSO watchers may be interested because the company executives are engaging directly with investors at a life sciences conference, providing an opportunity to share updates on the company.
PRNewsWire · 3 Sept 2026neutral
CytoSorbents Corporation announced a previously shareholder-approved one-for-20 reverse stock split of its common stock, intended to support compliance with Nasdaq's $1.00 minimum bid price requirement. The split is expected to become effective and trade on a split-adjusted basis at the market open on September 8, 2026.
Why it matters — The reverse split is a significant corporate action aimed at maintaining compliance with Nasdaq listing requirements, which directly affects CTSO shareholders' holdings and the stock's trading structure.
